News|Articles|October 29, 2021

CHMP Recommends Booster Dose Consideration for Moderna COVID-19 Vaccine

Author(s)Pharmaceutical Technology Editors

EMA’s CHMP concluded that a booster dose of Moderna’s Spikevax vaccine may be considered in people aged 18 and older.

The European Medical Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on Oct. 25th, 2021, that a booster dose of Moderna’s COVID-19 vaccine, Spikevax, may be considered in people 18 or older.

According to an agency press release, this decision was made following data showing that a third dose of Spikevax given six to eight months after the second dose led to a rise in antibody levels in adults with waning antibody levels. While CHMP stated that the data indicated that side effects following a booster are similar to what occurs after a second dose, rare side effects (such as inflammatory heart conditions) are being carefully monitored.

Following this recommendation, European public health bodies may issue official recommendations on booster doses at a national level. Earlier this month, EMA issued a similar recommendation for Comirnaty, the Pfizer-BioNTech COVID-19 vaccine.

Source: EMA

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

Ravulizumab gains FDA accelerated approval for IgA nephropathy after it cut proteinuria by 43.4%.

October 22nd, 2026

Ravulizumab's IgA Nephropathy Approval Expands Large-Molecule Biologic Demand

FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.

FDA approves GSK’s bepirovirsen for hepatitis B, putting antisense oligonucleotide scale-up in focus.

October 21st, 2026

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

October 20th, 2026

Drug-Device Combination Apps: The FDA's 3 Questions for Sponsors

FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.

October 19th, 2026

Expedited IND Pilot Targets Sequential Delays Slowing First-in-Human Trials

Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.

October 22nd, 2026

Ask the Expert: Choosing Ingredient Suppliers

Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.